{ "schema_version": 1, "kind": "condition", "id": "superficial-thrombophlebitis", "name": "Superficial Venous Thrombophlebitis", "category": "chronic", "sources": "CHEST Guidelines: Antithrombotic Therapy for VTE Disease 2021 · Diclofenac sodium 50 mg delayed-release (gastro-resistant) tablets US prescribing information, DOSAGE AND ADMINISTRATION (DailyMed SetID a57b897e-0cbe-4ac3-969f-b00357a0cfa8) · Ibuprofen 400 mg film-coated tablets (POM) SmPC section 4.2 (eMC product 7020) · CHEST Antithrombotic Therapy for VTE Disease, second update 2021, superficial vein thrombosis recommendation (as reported in AAFP POEM, Am Fam Physician 2022 Aug)", "review_status": "reviewed", "verified_against": "Diclofenac sodium 50 mg delayed-release (gastro-resistant) tablets US prescribing information, DOSAGE AND ADMINISTRATION (DailyMed SetID a57b897e-0cbe-4ac3-969f-b00357a0cfa8) · Ibuprofen 400 mg film-coated tablets (POM) SmPC section 4.2 (eMC product 7020) · CHEST Antithrombotic Therapy for VTE Disease, second update 2021, superficial vein thrombosis recommendation (as reported in AAFP POEM, Am Fam Physician 2022 Aug) · Superficial Thrombophlebitis - disease-level clinical article (superficial-thrombophlebitis-clinical.txt) · Egyptian National Drug Formulary - Blood 2025", "verified_date": "2026-08", "treatments": [ { "id": 1680, "generic": "Diclofenac", "line": 1, "is_adjunct": false, "form": "oral.solid", "strength_mg": 50.0, "adult_dose": "50 mg orally two to three times daily with food", "adult_duration": "7-10 days", "dose_source": "Diclofenac sodium 50 mg delayed-release (gastro-resistant) tablets US prescribing information, DOSAGE AND ADMINISTRATION (DailyMed SetID a57b897e-0cbe-4ac3-969f-b00357a0cfa8)", "rationale": "NSAID that inhibits COX-mediated prostaglandin synthesis to relieve the local pain, redness, and swelling of an inflamed superficial vein; an oral option for superficial thrombophlebitis when there is no cardiovascular contraindication.", "cautions": [ "Do not exceed 150 mg daily; take with food or PPI cover in patients at risk for gastric mucosal damage.", "Contraindicated in established ischemic heart disease, peripheral arterial disease, cerebrovascular disease, or severe heart failure.", "CONTRAINDICATED in established heart failure (NYHA II-IV), ischaemic heart disease, peripheral arterial disease and cerebrovascular disease. Arterial thrombotic risk rises with dose and duration - use the lowest dose for the shortest time, and never exceed 150 mg a day." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Specialist pediatric hematology referral required.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "DECLOFENAC 50MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EL NASR", "price_egp": 12.0, "pack_count": 20, "unit_price": 0.6, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "RHEUMARENE 50MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SEDICO", "price_egp": 13.5, "pack_count": 20, "unit_price": 0.68, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DICLORAPID 50MG 30 F.C.TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SPIMACO MISR", "price_egp": 37.5, "pack_count": 30, "unit_price": 1.25, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ZITOXANAL 50 MG 30 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ARAB CAPS > SUECAL PHARMA", "price_egp": 69.0, "pack_count": 30, "unit_price": 2.3, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "RHUMAQUICK 50 MG 20 DISP. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MEDIZEN PHARMACEUTICAL INDUSTRIES", "price_egp": 21.0, "pack_count": null, "unit_price": null, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "OFLAM 50 MG 20 QUICKETAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MUP > ACINO", "price_egp": 48.0, "pack_count": null, "unit_price": null, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DECLOPHEN FAST 50MG GR. FOR ORAL SUSP. 30 SACHETS", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "PHARCO", "price_egp": 102.0, "pack_count": null, "unit_price": null, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ACTIFAST 50 MG 30 SACHETS", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA > OCTOBER PHARMA", "price_egp": 105.0, "pack_count": null, "unit_price": null, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "CATAFLAM 15MG/ML ORAL DROPS 15 ML", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "NOVARTIS", "price_egp": 10.0, "pack_count": null, "unit_price": null, "strength_mg": 15.0, "exact_strength": false, "exact_form": false, "discontinued": false, "also_contains": null }, { "trade_name": "DOLPHIN K 15MG/ML ORAL DROPS 15 ML", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "DELTA PHARMA", "price_egp": 11.25, "pack_count": null, "unit_price": null, "strength_mg": 15.0, "exact_strength": false, "exact_form": false, "discontinued": false, "also_contains": null } ], "condition_id": "superficial-thrombophlebitis" }, { "id": 1681, "generic": "Ibuprofen", "line": 1, "is_adjunct": false, "form": "oral.solid", "strength_mg": 400.0, "adult_dose": "400 mg orally three times daily with food", "adult_duration": "10-14 days", "dose_source": "Ibuprofen 400 mg film-coated tablets (POM) SmPC section 4.2 (eMC product 7020)", "rationale": "NSAID first-line choice for a localised superficial thrombophlebitis away from the deep venous system; inhibits COX-mediated prostaglandin synthesis to reduce the local inflammation and pain of the thrombosed vein.", "cautions": [ "First-line for a localised superficial thrombophlebitis - short, and not near a deep vein. The distance from the saphenofemoral junction that counts as 'near' is arbitrary and the literature says so: 3 cm and 5 cm are both in use. Treat proximity to the junction as the question, not the exact centimetre.", "Perform venous duplex ultrasonography to measure thrombus extent and rule out coexisting deep vein thrombosis (DVT) or proximity to deep venous junctions.", "Contraindicated in active peptic ulceration, severe renal impairment, severe heart failure, or third trimester of pregnancy.", "Combine with supportive measures including warm compresses, limb elevation, and graduated compression stockings once acute infection/suppuration is excluded." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Superficial vein thrombosis is extremely rare in pediatric patients; urgent pediatric hematology referral is required to investigate underlying hypercoagulability or venous anomalies.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "DAJUANOFEN 400 MG 20 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "COPAD PHARMA", "price_egp": 5.0, "pack_count": 20, "unit_price": 0.25, "strength_mg": 400.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "FLABU 400MG 10 F.C.TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "DELTA PHARMA", "price_egp": 3.75, "pack_count": 10, "unit_price": 0.38, "strength_mg": 400.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "NOVA-PROFEN 400MG 30 F.C. TABLETS", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI", "price_egp": 12.75, "pack_count": 30, "unit_price": 0.42, "strength_mg": 400.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "IBUPROFEN 400 MG 10 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SEDICO", "price_egp": 6.0, "pack_count": 10, "unit_price": 0.6, "strength_mg": 400.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "MAFO 400 MG 30 F.C.TABS", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EIPICO", "price_egp": 42.0, "pack_count": 30, "unit_price": 1.4, "strength_mg": 400.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "BRUFEN 400 MG 30 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "KAHIRA > ABBOTT LABORATORIES", "price_egp": 78.0, "pack_count": 30, "unit_price": 2.6, "strength_mg": 400.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "PROFUSOL 400MG 20 S.G CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EUROPEAN EGYPTIAN PHARM. IND.", "price_egp": 31.0, "pack_count": null, "unit_price": null, "strength_mg": 400.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ANALGIPROF 400 MG 25 SACHETS", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EVA PHARMA", "price_egp": 37.5, "pack_count": null, "unit_price": null, "strength_mg": 400.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "NOVA-PROFEN 100MG/5ML ORAL SUSP. 100ML", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI", "price_egp": 2.25, "pack_count": null, "unit_price": null, "strength_mg": 100.0, "exact_strength": false, "exact_form": false, "discontinued": false, "also_contains": null }, { "trade_name": "BRUFEMOL-N SUSP. 60 ML", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ARAB DRUG COMPANY (ADCO)", "price_egp": 4.5, "pack_count": null, "unit_price": null, "strength_mg": null, "exact_strength": false, "exact_form": false, "discontinued": false, "also_contains": null } ], "condition_id": "superficial-thrombophlebitis" }, { "id": 1684, "generic": "Referral & safety-netting (no drug therapy)", "line": 1, "is_adjunct": false, "form": null, "strength_mg": null, "adult_dose": null, "adult_duration": null, "dose_source": "Superficial Thrombophlebitis - disease-level clinical article (superficial-thrombophlebitis-clinical.txt)", "rationale": "Carries the referral criteria and warning signs for this condition, which apply whichever treatment is chosen.", "cautions": [ "RED FLAG - Concomitant DVT is common with SVT and ultrasound evaluation is recommended; SVT within 3 cm of the saphenofemoral junction should be treated as DVT.", "RED FLAG - A first episode of thrombophlebitis in a patient over 40, or migratory thrombophlebitis, calls for malignancy evaluation." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": null, "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [], "condition_id": "superficial-thrombophlebitis" }, { "id": 1682, "generic": "Rivaroxaban", "line": 2, "is_adjunct": false, "form": "oral.solid", "strength_mg": 10.0, "adult_dose": "10 mg once daily", "adult_duration": "45 days", "dose_source": "CHEST Antithrombotic Therapy for VTE Disease, second update 2021, superficial vein thrombosis recommendation (as reported in AAFP POEM, Am Fam Physician 2022 Aug)", "rationale": "The anticoagulant to reach for when the clot is extensive - 5 cm or more, or close to the saphenofemoral junction. CHEST names it alongside fondaparinux as an equal option, and in Egypt the difference is the whole decision: 45 days of rivaroxaban is about 342 EGP in tablets, 45 days of fondaparinux is about 6,219 EGP in daily injections. Same guideline, same recommendation strength, eighteen times the price.", "cautions": [ "Duplex ultrasound before starting. This dose treats superficial vein thrombosis; a coexisting deep vein thrombosis needs the full treatment dose, and starting the low one on an undiagnosed DVT under-treats it.", "Contraindicated in active clinically significant bleeding and in severe renal impairment (creatinine clearance under 15 mL/min).", "The 10 mg tablet does not need to be taken with food - unlike the 15 mg and 20 mg strengths used for deep vein thrombosis, which do.", "Ask about every other anticoagulant and antiplatelet before starting, and about NSAIDs - the two rows above this one are NSAIDs, and the combination raises bleeding risk." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not for children. Superficial thrombophlebitis in a child is uncommon and warrants paediatric assessment rather than anticoagulation in primary care.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "ANDORIVABAN 10 MG 20 TABS", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ANDALOUS PHARMA", "price_egp": 152.0, "pack_count": 20, "unit_price": 7.6, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "REPATOXABAN 10 MG 10 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "HORUS FOR PHARMACEUTICAL PRODUCTS", "price_egp": 105.0, "pack_count": 10, "unit_price": 10.5, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "RIVAFLOWVA 10 MG 20 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "GYPTO PHARMA", "price_egp": 210.0, "pack_count": 20, "unit_price": 10.5, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ELIPROXABAN 10 MG 20 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA > SATO PHARMA", "price_egp": 260.0, "pack_count": 20, "unit_price": 13.0, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "VAROXABAN 10 MG 10 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EL-OBOUR", "price_egp": 130.0, "pack_count": 10, "unit_price": 13.0, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "XANOXIBAN 10 MG 10 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "HIKMA PHARMA", "price_egp": 171.0, "pack_count": 10, "unit_price": 17.1, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "XARELTO 10 MG 10 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "BAYER HEALTHCARE", "price_egp": 421.0, "pack_count": 10, "unit_price": 42.1, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "RIVABEDAX 10 MG 30 ODT", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "AVERROES PHARMA", "price_egp": 259.5, "pack_count": null, "unit_price": null, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "superficial-thrombophlebitis" }, { "id": 1685, "generic": "Fondaparinux", "line": 2, "is_adjunct": false, "form": "injection", "strength_mg": 2.5, "adult_dose": "2.5 mg subcutaneously once daily", "adult_duration": "30 to 45 days", "dose_source": "Egyptian National Drug Formulary - Blood 2025", "rationale": "Fondaparinux is recommended by the Cochrane review for higher-risk superficial thrombophlebitis; the formulary lists it for treatment of superficial-vein thrombosis at 2.5 mg daily for up to 45 days.", "cautions": [ "Hypersensitivity to the active substance or to any of the excipients.", "Active major bleeding.", "Severe renal impairment defined by creatinine clearance < 20 ml/min.", "Patients with body weight < 50 kg: has not been studied. Use is not recommended." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "No safety and efficacy data for use in children below 17 years.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "ARIXTRA 2.5MG/0.5ML 10 S.C. PREFILLED SYRINGES", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ASPEN PHARMA TRADING LIMITED > PHOENIX GROUP", "price_egp": 1382.0, "pack_count": null, "unit_price": null, "strength_mg": 2.5, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "superficial-thrombophlebitis" }, { "id": 1683, "generic": "Enoxaparin sodium", "line": 3, "is_adjunct": false, "form": "injection", "strength_mg": 40.0, "adult_dose": "40 mg (4000 IU) subcutaneously once daily", "adult_duration": "45 days", "dose_source": "CHEST Antithrombotic Therapy for VTE Disease, second update 2021, superficial vein thrombosis recommendation (as reported in AAFP POEM, Am Fam Physician 2022 Aug)", "rationale": "Third choice, and only where an oral anticoagulant will not do - pregnancy, malabsorption, or a patient who cannot be relied on to swallow it. CHEST suggests fondaparinux 2.5 mg daily over a prophylactic dose of low-molecular-weight heparin, so this is not the guideline's preference. Fondaparinux is registered in Egypt as ARIXTRA 2.5 mg at about 1,382 EGP for 10 syringes, which is 45 daily injections at roughly 6,219 EGP for the course - the reason it is not the first thing offered here either.", "cautions": [ "Mandatory venous duplex ultrasound prior to therapy to document thrombus length >= 5 cm or involvement near saphenofemoral junction.", "Contraindicated in active major bleeding, severe heparin-induced thrombocytopenia (HIT) history, or severe uncorrected bleeding diathesis.", "Monitor renal function (reduce dose if CrCl < 30 mL/min) and platelet count." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Pediatric venous thrombosis requires immediate specialist pediatric hematology hospital referral.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "EXAPINE 40MG/0.4ML 2 PREFILLED SYRINGES", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "WADI ELNEEL BENTA", "price_egp": 185.0, "pack_count": null, "unit_price": null, "strength_mg": 40.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "CLEXANE 40MG/0.4ML 2 PREFILLED SYRINGES", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI", "price_egp": 311.0, "pack_count": null, "unit_price": null, "strength_mg": 40.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "superficial-thrombophlebitis" } ] }